A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia
Nobuko Hijiya(Lurie Children's Hospital), William L. Carroll(NYU Langone Health), Richard Kadota(Roswell Park Comprehensive Cancer Center), Todd M. Cooper(Seattle Children's Hospital), Roland Chu(Children's Hospital of Michigan), Elly Barry, Sima Jeha(St. Jude Children's Research Hospital), Rekha Abichandani, Brian J. Thomson(Planetary Science Institute), L. B. Silverman(Kettering University), Michael Rytting(The University of Texas MD Anderson Cancer Center), Paul S. Gaynon(University of Southern California), Violet Shen(Ruhr University Bochum), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center)
Cited by 86
Related Papers
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
|Nature Genetics|2017|934
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920